Table 1 Participant characteristics.
From: Blood biomarkers of neuronal injury and astrocytic reactivity in electroconvulsive therapy
ECT participants (N = 99) | Controls (N = 99) | p value | |
|---|---|---|---|
Age, mean (sd) | 46.7 (16.1) | 42.7 (13.2) | 0.089 |
Female sex | 68 (68.7%) | 68 (68.7%) | 1.000 |
Diagnosis | |||
Bipolar depression | 15 (15.2%) | ||
Unipolar depression | 84 (84.8%) | ||
MADRS-S before ECTa, mean (sd) | 34.4 (7.4) | ||
MADRS-S after ECT, mean (sd) | 16.4 (11.0) | ||
MADRS-S responseb | 56 (58.2%) | ||
MADRS-S remission | 33 (33%) | ||
GSE-My after ECT | 3.2 (1.1) | ||
Previous history of ECTb | 41 (41.4%) | ||
Number of ECT sessions, mean (sd) | 8.7 (2.5) | ||
Treatment parameters at first session | |||
Bilateral ECT | 2 (2.0%) | ||
Pulse width | |||
0.25–0.49 ms | 18 (18.2%) | ||
0.5 ms | 67 (67.7%) | ||
0.51–1.0 ms | 14 (14.1%) | ||
Electric charge (mC), mean (sd) | 255.2 (103.1) | ||
Seizure time (EEG, s), mean (sd) | 45 (31–59) | ||
Medication before ECT | |||
Lithium | 17 (17.2%) | ||
Valproic acid | 3 (3.0%) | ||
Lamotrigine | 7 (7.1%) | ||
Second generation antipsychotic | 32 (32.3%) | ||
First generation antipsychotic | 8 (8.1%) | ||
Antidepressant | 84 (84.8%) | ||
